Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis

Main Article Content

Alessandro Laganà
Giovanni Manfredi Assanto
Mauro Passucci
Cristina Santoro
Antonio Chistolini

Keywords

VTE Predict score, Direct oral anticoagulants (DOACs), Key words: direct oral anticoagulants, thrombophilia, thromboembolism, venous thrombosis

Downloads

Download data is not yet available.


Abstract 658
PDF Downloads 115
HTML Downloads 7

References

1. De Winter MA, Büller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, Kakkar AK, Middeldorp S, Raskob GE, Sørensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M; VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 Apr 7;44(14):1231-1244.

2. Laganà A, Assanto GM, Masucci C, et al. Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up. Mediterr J Hematol Infect Dis. 2024;16(1):e2024020.